Wednesday 17 March

Thursday 18 March

Friday 19 March

Session 1:

Managing treatment in patients with low or undetectable viral load

Invited lecture: Switching therapy due to toxicity in patients with undetectable viral load – The virologist’s perspective

AM. Geretti

Pres.

Invited lecture: Switching therapy due to toxicity in patients with undetectable viral load – The clinician’s perspective

M. Youle

N.A

Efficiency of HIV-1 PR-RT genotyping on clinical isolates with viral load less than 1000 copies/mL: A 12 year analysis

T. Pattery

Abs.

Pres.

Clinical case presentation: Resistance testing at low viral load: a case story

A. De Luca

Pres.

Session 2:

Mechanisms of HIV Drug Resistance

Invited lecture: Clinical implications of resistance to the NNRTIs

C.F. Perno

Pres.

Rare HIV-1 drug resistance mutations exert subtle synergistic and antagonistic effects in the context of the genetic background

M. van Houtte

Abs.

Pres.

Resistance mutations in the viral protease alter the in vitro resistance profiles of bevirimat

A. Fun

Abs.

Pres.

Genetic diversity and multi-drug class resistance of a large HIV-1 sequence repository

K. van der Borght

Abs.

Pres.

New HIV-1 gp120 V3 signatures modulate co-receptor usage and the interaction with CCR5 N-terminus

V. Svicher

Abs.

N.A.